Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P15169

UPID:
CBPN_HUMAN

ALTERNATIVE NAMES:
Anaphylatoxin inactivator; Arginine carboxypeptidase; Carboxypeptidase N polypeptide 1; Carboxypeptidase N small subunit; Kininase-1; Lysine carboxypeptidase; Plasma carboxypeptidase B; Serum carboxypeptidase N

ALTERNATIVE UPACC:
P15169; B1AP59

BACKGROUND:
The Carboxypeptidase N catalytic chain, with aliases such as Arginine carboxypeptidase and Lysine carboxypeptidase, is pivotal in protecting the body from inflammatory and vasoactive peptides. Its function is to deactivate peptides containing C-terminal Arg or Lys, crucial in regulating inflammatory responses.

THERAPEUTIC SIGNIFICANCE:
Linked to Carboxypeptidase N deficiency, characterized by a spectrum of symptoms including angioedema and asthma, this protein's gene mutations suggest a direct role in the disease's pathogenesis. Exploring Carboxypeptidase N's function offers promising avenues for developing novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.